Logo image of XTNT

XTANT MEDICAL HOLDINGS INC (XTNT) Stock Fundamental Analysis

NYSEARCA:XTNT - NYSE Arca - US98420P3082 - Common Stock - Currency: USD

0.56  -0.03 (-5.25%)

After market: 0.5898 +0.03 (+5.32%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to XTNT. XTNT was compared to 190 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of XTNT have multiple concerns. While showing a medium growth rate, XTNT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

XTNT had negative earnings in the past year.
In the past year XTNT has reported a negative cash flow from operations.
XTNT had negative earnings in 4 of the past 5 years.
In the past 5 years XTNT reported 4 times negative operating cash flow.
XTNT Yearly Net Income VS EBIT VS OCF VS FCFXTNT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M -60M -80M

1.2 Ratios

The Return On Assets of XTNT (-17.79%) is comparable to the rest of the industry.
XTNT has a Return On Equity of -38.46%. This is comparable to the rest of the industry: XTNT outperforms 53.72% of its industry peers.
Industry RankSector Rank
ROA -17.79%
ROE -38.46%
ROIC N/A
ROA(3y)-7.41%
ROA(5y)-11.65%
ROE(3y)-13.08%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
XTNT Yearly ROA, ROE, ROICXTNT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100 200

1.3 Margins

XTNT has a better Gross Margin (60.89%) than 60.64% of its industry peers.
In the last couple of years the Gross Margin of XTNT has remained more or less at the same level.
XTNT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.89%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.97%
GM growth 5Y0.17%
XTNT Yearly Profit, Operating, Gross MarginsXTNT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50

More info and screens

2

2. Health

2.1 Basic Checks

XTNT does not have a ROIC to compare to the WACC, probably because it is not profitable.
XTNT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, XTNT has more shares outstanding
The debt/assets ratio for XTNT has been reduced compared to a year ago.
XTNT Yearly Shares OutstandingXTNT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
XTNT Yearly Total Debt VS Total AssetsXTNT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M

2.2 Solvency

XTNT has an Altman-Z score of -1.56. This is a bad value and indicates that XTNT is not financially healthy and even has some risk of bankruptcy.
XTNT has a Altman-Z score of -1.56. This is in the lower half of the industry: XTNT underperforms 60.11% of its industry peers.
A Debt/Equity ratio of 0.42 indicates that XTNT is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.42, XTNT perfoms like the industry average, outperforming 42.55% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.42
Debt/FCF N/A
Altman-Z -1.56
ROIC/WACCN/A
WACC9.89%
XTNT Yearly LT Debt VS Equity VS FCFXTNT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 2.12 indicates that XTNT has no problem at all paying its short term obligations.
XTNT has a Current ratio of 2.12. This is in the lower half of the industry: XTNT underperforms 62.77% of its industry peers.
XTNT has a Quick Ratio of 2.12. This is a bad value and indicates that XTNT is not financially healthy enough and could expect problems in meeting its short term obligations.
XTNT has a worse Quick ratio (0.88) than 84.04% of its industry peers.
Industry RankSector Rank
Current Ratio 2.12
Quick Ratio 0.88
XTNT Yearly Current Assets VS Current LiabilitesXTNT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

6

3. Growth

3.1 Past

XTNT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1400.00%.
Looking at the last year, XTNT shows a very strong growth in Revenue. The Revenue has grown by 45.11%.
Measured over the past years, XTNT shows a small growth in Revenue. The Revenue has been growing by 4.81% on average per year.
EPS 1Y (TTM)-1400%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-157.14%
Revenue 1Y (TTM)45.11%
Revenue growth 3Y19.62%
Revenue growth 5Y4.81%
Sales Q2Q%11.66%

3.2 Future

The Earnings Per Share is expected to grow by 16398600.00% on average over the next years. This is a very strong growth
Based on estimates for the next years, XTNT will show a very strong growth in Revenue. The Revenue will grow by 21.91% on average per year.
EPS Next Y-1690471156129789700%
EPS Next 2Y-7172804243.01%
EPS Next 3Y16398600%
EPS Next 5YN/A
Revenue Next Year30.92%
Revenue Next 2Y21.67%
Revenue Next 3Y21.91%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
XTNT Yearly Revenue VS EstimatesXTNT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M
XTNT Yearly EPS VS EstimatesXTNT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -5 -10 -15 -20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XTNT. In the last year negative earnings were reported.
Also next year XTNT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XTNT Price Earnings VS Forward Price EarningsXTNT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XTNT Per share dataXTNT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8

4.3 Compensation for Growth

A more expensive valuation may be justified as XTNT's earnings are expected to grow with 16398600.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7172804243.01%
EPS Next 3Y16398600%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XTNT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XTANT MEDICAL HOLDINGS INC

NYSEARCA:XTNT (2/21/2025, 8:04:00 PM)

After market: 0.5898 +0.03 (+5.32%)

0.56

-0.03 (-5.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)03-11 2025-03-11/bmo
Inst Owners12.22%
Inst Owner Change-1.55%
Ins Owners7.83%
Ins Owner Change-0.67%
Market Cap77.85M
Analysts85
Price Target2.3 (310.71%)
Short Float %0.19%
Short Ratio0.91
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-51.96%
Min EPS beat(2)-56.86%
Max EPS beat(2)-47.06%
EPS beat(4)0
Avg EPS beat(4)-54.41%
Min EPS beat(4)-96.08%
Max EPS beat(4)-17.65%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-2.12%
Min Revenue beat(2)-6.52%
Max Revenue beat(2)2.29%
Revenue beat(4)3
Avg Revenue beat(4)1.42%
Min Revenue beat(4)-6.52%
Max Revenue beat(4)6.12%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-200%
EPS NY rev (1m)-15%
EPS NY rev (3m)-15%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.7%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.68
P/FCF N/A
P/OCF N/A
P/B 1.7
P/tB 2.63
EV/EBITDA N/A
EPS(TTM)-0.13
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)-0.12
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS0.82
BVpS0.33
TBVpS0.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.79%
ROE -38.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.89%
FCFM N/A
ROA(3y)-7.41%
ROA(5y)-11.65%
ROE(3y)-13.08%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.97%
GM growth 5Y0.17%
F-Score3
Asset Turnover1.15
Health
Industry RankSector Rank
Debt/Equity 0.42
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 92.94%
Cap/Sales 3.34%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.12
Quick Ratio 0.88
Altman-Z -1.56
F-Score3
WACC9.89%
ROIC/WACCN/A
Cap/Depr(3y)113.73%
Cap/Depr(5y)88.69%
Cap/Sales(3y)2.82%
Cap/Sales(5y)2.54%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1400%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-157.14%
EPS Next Y-1690471156129789700%
EPS Next 2Y-7172804243.01%
EPS Next 3Y16398600%
EPS Next 5YN/A
Revenue 1Y (TTM)45.11%
Revenue growth 3Y19.62%
Revenue growth 5Y4.81%
Sales Q2Q%11.66%
Revenue Next Year30.92%
Revenue Next 2Y21.67%
Revenue Next 3Y21.91%
Revenue Next 5YN/A
EBIT growth 1Y-73.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year75.41%
EBIT Next 3Y36.56%
EBIT Next 5YN/A
FCF growth 1Y-277.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-412.39%
OCF growth 3YN/A
OCF growth 5YN/A